Syngene International Ltd

On a consolidated basis, net profit of Syngene International declined 2.81% to Rs 183.30 crore while net sales rose 11.03% to Rs 1018 crore in Q4 March 2025 over Q4 March 2024. Reported EBITDA rose 9% year-on-year to Rs 363 crore in Q4 March 2025. EBITDA margin (%) stood at 35% in Q4FY25, lower than 35.7% in Q4FY24. For the full year, net profit declined 2.71% to Rs 496.20 crore while net sales rose 4.41% to Rs 3642.40 crore in the year ended March 2025 over the year ended March 2024. Reported EBITDA rose 1% year-on-year to Rs 1,114 crore in FY25. EBITDA margin (%) stood at 30% in FY25, lower than 30.9% in FY24. In its outlook for FY26, the Syngene management anticipates the reported revenue growth will likely be in the mid-single digits. They also foresee the EBITDA margin moderating from current levels to the mid-twenties and a year-on-year decline in profit after tax. Commenting on the results, Peter Bains, managing director and CEO, Syngene International, said, Looking at the year ahead, while the wider global market dynamics remain uncertain, we expect the business momentum to continue with pipeline build in both small and large molecules, supported by new pilot programs and conversion of existing pilots in discovery services. On an underlying basis for fiscal year 2026, we expect revenue growth in the early teens reflecting a broad-based growth across research, development and manufacturing services. Adjusted for inventory balancing in large molecule commercial manufacturing at client level, the reported revenue growth is likely to be at mid-single digit. Deepak Jain, chief financial officer, Syngene International, said, Looking ahead into the next financial year, we expect the momentum to continue, with reported revenue growth at the mid-single digit level. As we bring the new biologics manufacturing facilities into operations, the additional operating costs and depreciation will impact margins. With this, we expect EBITDA margin to moderate from current levels to the mid-twenties and year-on-year decline in profit after tax. The company's board recommended a final dividend of Re 1.25 per equity share for the financial year 2024-25. Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Powered by Capital Market - Live

Nava Ltd, 360 ONE WAM Ltd, KFin Technologies Ltd and Can Fin Homes Ltd are among the other losers in the BSE's 'A' group today, 24 April 2025.Syngene International Ltd lost 13.07% to Rs 652 at 14:47 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 6.27 lakh shares were traded on the counter so far as against the average daily volumes of 16486 shares in the past one month.Nava Ltd tumbled 4.70% to Rs 470.05. The stock was the second biggest loser in 'A' group.On the BSE, 37641 shares were traded on the counter so far as against the average daily volumes of 34596 shares in the past one month.360 ONE WAM Ltd crashed 4.30% to Rs 1015.75. The stock was the third biggest loser in 'A' group.On the BSE, 62266 shares were traded on the counter so far as against the average daily volumes of 68845 shares in the past one month.KFin Technologies Ltd fell 4.26% to Rs 1231.55. The stock was the fourth biggest loser in 'A' group.On the BSE, 73027 shares were traded on the counter so far as against the average daily volumes of 1.36 lakh shares in the past one month.Can Fin Homes Ltd plummeted 4.26% to Rs 713. The stock was the fifth biggest loser in 'A' group.On the BSE, 39072 shares were traded on the counter so far as against the average daily volumes of 20594 shares in the past one month.Powered by Capital Market - Live

Natco Pharma Ltd, Newgen Software Technologies Ltd, MMTC Ltd, Glaxosmithkline Pharmaceuticals Ltd are among the other stocks to see a surge in volumes on NSE today, 24 April 2025.Syngene International Ltd registered volume of 168.31 lakh shares by 14:14 IST on NSE, a 34.31 fold spurt over two-week average daily volume of 4.91 lakh shares. The stock slipped 12.51% to Rs.655.45. Volumes stood at 6.35 lakh shares in the last session.Natco Pharma Ltd clocked volume of 144.27 lakh shares by 14:14 IST on NSE, a 34.05 times surge over two-week average daily volume of 4.24 lakh shares. The stock gained 8.94% to Rs.920.00. Volumes stood at 3.69 lakh shares in the last session.Newgen Software Technologies Ltd saw volume of 117.97 lakh shares by 14:14 IST on NSE, a 28.87 fold spurt over two-week average daily volume of 4.09 lakh shares. The stock increased 13.03% to Rs.1,122.60. Volumes stood at 14 lakh shares in the last session.MMTC Ltd registered volume of 410.32 lakh shares by 14:14 IST on NSE, a 26.01 fold spurt over two-week average daily volume of 15.78 lakh shares. The stock rose 14.15% to Rs.63.73. Volumes stood at 14.89 lakh shares in the last session.Glaxosmithkline Pharmaceuticals Ltd recorded volume of 17.98 lakh shares by 14:14 IST on NSE, a 14.9 times surge over two-week average daily volume of 1.21 lakh shares. The stock gained 3.19% to Rs.2,937.50. Volumes stood at 85241 shares in the last session.Powered by Capital Market - Live

Syngene International announced that the 32nd Annual General Meeting(AGM) of the company will be held on 23 July 2025.Powered by Capital Market - Live

Syngene International announced that the Board of Directors of the Company at its meeting held on 23 April 2025, inter alia, have recommended the final dividend of Rs 1.25 per equity Share (i.e. 12.5%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Syngene International declined 2.81% to Rs 183.30 crore in the quarter ended March 2025 as against Rs 188.60 crore during the previous quarter ended March 2024. Sales rose 11.03% to Rs 1018.00 crore in the quarter ended March 2025 as against Rs 916.90 crore during the previous quarter ended March 2024. For the full year,net profit declined 2.71% to Rs 496.20 crore in the year ended March 2025 as against Rs 510.00 crore during the previous year ended March 2024. Sales rose 4.41% to Rs 3642.40 crore in the year ended March 2025 as against Rs 3488.60 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1018.00916.90 11 3642.403488.60 4 OPM %33.7534.56 -28.6029.08 - PBDT346.60320.10 8 1060.501057.80 0 PBT240.50209.00 15 627.90631.90 -1 NP183.30188.60 -3 496.20510.00 -3 Powered by Capital Market - Live

Syngene International has fixed 27 June 2025 as record date for payment of final dividend of Re.1.25/- per equity share of Rs. 10/- for the financial year 2024-25. Powered by Capital Market - Live

Syngene International will hold a meeting of the Board of Directors of the Company on 23 April 2025.Powered by Capital Market - Live

Peter Bains, with over 30 years of global experience in biopharmaceuticals, was appointed group CEO of Biocon in September 2023. Holding a bachelor's degree in science from the University of Sheffield, Bains previously served as CEO of Syngene International, where he led its public listing in 2015. He has also held leadership roles at Sosei Group and GlaxoSmithKline. Bains rejoined Biocon as an independent director in December 2022 before being appointed CEO. Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The company reported a 17.58% increase in consolidated net profit to Rs 131.1 crore in Q3 FY25 as compared with Rs 111.5 crore in Q3 FY24. Revenue from operations jumped 10.57% YoY to Rs 943.7 crore in Q3 FY25. Shares of Syngene International rose 0.95% to Rs 725 on the BSE.Powered by Capital Market - Live

The state-of-the-art facility, located in Baltimore, Maryland, was acquired by Syngene USA Inc., a wholly owned subsidiary of Syngene, from Emergent Manufacturing Operations Baltimore, LLC, a subsidiary of Emergent BioSolutions Inc. The newly acquired site is equipped with multiple monoclonal antibody (mAb) manufacturing lines and will increase Syngene's single-use bioreactor capacity to 50,000L, enhancing its ability to support large molecule discovery, development, and manufacturing services. The facility will play a crucial role in Syngene's global operations, providing continuity of supply alongside the company's existing facilities in India and North America. With the acquisition, Syngene strengthens its ability to serve both human and animal health market segments, offering a range of services, including cell line development, process optimization, and clinical and commercial supply. This expansion highlights Syngene's strategic commitment to the U.S. market and aims to foster deeper economic ties between India and the United States, benefiting both countries' life sciences sectors. The total investment in the U.S. facility is estimated at $50 million, including the acquisition cost of $36.5 million and expenses related to making the site operational. The acquisition is expected to close in March 2025, pending customary closing conditions. The upgraded Baltimore facility, strategically located near key biotech hubs in the Northeast, is anticipated to be operational for client projects by the second half of 2025. The firm anticipates the site will see demand from innovative U.S. mAb developers requiring direct access for onshore production, as well as international innovators who want a U.S.-based manufacturing option. This complements the capabilities and capacity available across its facilities in Bengaluru. As part of the agreement, Emergent BioSolutions itself has the right to secure manufacturing capacity from the facility in the future, representing offtake potential from U.S.-based innovators. It will also support the growing animal health segment, in which a U.S. site is often a key client requirement. The company said that investment in its first facility in the United States marks a strategic commitment to the U.S. market, with significant benefits for the local economy and the broader life sciences industry. The facility is expected to create jobs, stimulate local economic activity, and strengthen domestic biologic manufacturing capabilities while also contributing to pharmaceutical innovation and supply chain resilience. This investment highlights the potential for deeper economic collaboration between India and the United States, fostering sustained economic growth and advancing the shared goal of bolstering critical healthcare infrastructure. Peter Bains, CEO Designate, Syngene International, said, 'With one of the largest biologics R&D teams and commercial scale manufacturing capabilities in both India and the USA, we now offer a compelling and flexible solution for global pharma and biotech customers. This investment will enable Syngene to cater to growing client requirements in an expanding market. It will also provide clients access to the collective service capability of multiple geographic sites, scientists and experience.' Alex Del Priore, Senior Vice President ' Development & Manufacturing Services, Syngene International, said, 'This facility is a significant milestone for Syngene and comes in response to growing client demand in the United States, the fastest-growing biologics market. It strengthens our offering for animal health clients looking for USDA approval for their products. Most importantly, it increases the options we can offer our global customers, providing commercial-scale biologic manufacturing capabilities across our global network and will be underpinned by existing key client projects.' Deepak Jain, CFO, Syngene International, said, 'The investment will be synergistic with expected additional process development work that will be executed in India while manufacturing can be done in the US. The investment will be fully funded through internal accruals and cash. The company will continue to maintain a robust balance sheet, a low debt profile, and a comfortable safety margin for debt covenants post this investment. As we ramp up utilization, we expect asset turnover to grow to 1x in less than 5 years, with EBIT margins expected to be in line with the company average from FY30 and positively contribute to the bottom line. The acquisition will not materially impact the current financial guidance given for fiscal year 2024'2025. In the short term, we expect a minor dilution of operating margins as a result of costs to be incurred in this facility.' Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The company reported 17.58% increase in consolidated net profit to Rs 131.1 crore in Q3 FY25 as compared with Rs 111.5 crore in Q3 FY24. Revenue from operations jumped 10.57% YoY to Rs 943.7 crore in Q3 FY25. The counter rose 0.29% to Rs 680 on the BSE. Powered by Capital Market - Live